You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation
SBC: SYNZYME TECHNOLOGIES LLC Topic: 102DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A high resolution and high DQE detector optimized for mammography using single shot bi directional tri contrast imaging
SBC: SIGRAY, INC. Topic: NIBIBDESCRIPTION provided by applicant X ray tricontrast imaging provides three different modes of contrast absorption contrast the mechanism behind how conventional medical X ray imaging equipment images phase contrast which provides up to X more contrast than absorption based contrast for soft tissue and scatter contrast which provides information of features at dimensions smaller than ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Plasmid-seeded aligned nanofibrillar scaffold for acute muscle injury treatment
SBC: Fibralign Corporation Topic: DHP14009Based on encouraging Phase I feasibility results, we propose developing a novel gene therapy approach to promote guided vascular regeneration in treating extremities after traumatic injury. Our approach is to provide thread-like implants comprised of aligned nanofibrillar collagen scaffolds loaded with Hepatocyte Growth Factor (HGF) vectors (e.g., HGF DNA plasmid, modified mRNA) designed to enhanc ...
SBIR Phase II 2016 Department of DefenseDefense Health Agency -
Smart Femtosecond Fiber Laser Wound Healing System
SBC: POLARONYX INC Topic: DHP15B002Based on our success in developing the world first commercial high energy femtosecond fiber laser system and our leading proprietary technology development in ultrashort pulsed fiber laser material processing, PolarOnyx proposes, for the first time, a compact high energy fiber laser based smart wound healing tool to meet with the requirement of this DHP solicitation. It includes a high energy fs f ...
SBIR Phase I 2016 Department of DefenseDefense Health Agency -
Novel immunotherapy strategy for treatment of pancreatic cancer
SBC: Oncotab, Inc. Topic: NCIDESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
SBC: BIOVINC, LLC Topic: NIDCRDESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents
SBC: Capture Pharmaceuticals, Inc. Topic: 102DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mobile Intervention Kit to Increase HIV/HCV Testing and Overdose Prevention Training
SBC: Digital Health Empowerment, Inc Topic: NIDADESCRIPTION provided by applicant Because many people who inject drugs PWID do not receive adequate information about HIV or HCV testing and prevention or overdose prevention and response training we propose to develop a Mobile Intervention Kit to deliver technology based interventions from a library of theory guided video content The first iteration will address overdose prevention and r ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Targeted Epigenetic Therapy for Triple-Negative Breast Cancer
SBC: PARKSIDE SCIENTIFIC INC. Topic: 102DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health